We have developed internal assets ranging from mechanistic PK-PD models to multi-scale drug-disease models comprising multiple disease pathways, therapies and clinical end points of interest. This includes assets in oncology, immunology & inflammation and neuroscience. Models are only as good as the data available to calibrate & validate them. Alongside model development, we dedicate efforts to develop databases from public literature to help parameterize (bottom up data) and constrain (top down, usually clinical trial data) these models. Our models & databases are an accumulation of our experience over the years, and serve as a useful starting point for our client collaborations.